CLINICAL_TRIALS trial_result · 2020-11-09

Clinical Trial Update: Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4 [Phase 3]

This phase 3 multicenter study evaluated SER120 nasal spray formulations for nocturia; the trial has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Serenity Pharmaceuticals, Inc. | Conditions: Nocturia | Phase 3 | Status: COMPLETED | Results posted: 2020-11-09